Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization.
The human diploid cell rabies vaccine (HDCV) has been shown to be highly immunogenic when used for pre-exposure immunization. However, the high cost of the product and the adverse reactions seen following booster doses of HDCV have limited its use. A purified chick embryo cell (PCEC) rabies vaccine was compared with the HDCV by two routes of administration for reactogenicity, antibody response, duration of antibody, and anamestic response to boosters over a 2 year period. The study showed that the two vaccines were comparable in their immunogenicity and reactogenicity after initial three dose series. No adverse reactions were noted following the 2 year booster with PCEC. The PCEC can be produced at less than one-half the cost of the HDCV.
Dreesen
D W
DW
Department of Medical Microbiology, Center for Infectious Diseases, Atlanta, GA 30333.
Fishbein
D B
DB
Kemp
D T
DT
Brown
J
J
D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002642:Chick Embryo; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology*; D011897:Random Allocation
D000914:Antibodies, Viral; D011819:Rabies Vaccines